唑来膦酸在恶性肿瘤骨转移中的临床应用  

Clinical Application of Zoledronic Acid in Bone Metastasis of Malignant Tumor

作　　者：胡霜霜[1] 童卫杭[1] 王婷[1] 胡范文[1] 孙笑[1] 常子倩[1] 

机构地区：[1]第二炮兵总医院,北京100088

出　　处：《中国药师》2015年第9期1568-1570,共3页China Pharmacist

摘　　要：骨转移是恶性肿瘤常见并发症之一,在乳腺癌、肺癌、前列腺癌等发病率高达30%-85%。骨转移导致的持续疼痛及爆发痛,严重影响患者的生活质量。唑来膦酸是第三代双膦酸盐类药物,主要通过抑制破骨细胞的活性和诱导破骨细胞凋亡来抑制骨吸收。唑来膦酸治疗恶性肿瘤骨转移也越来越受到关注,并有良好的应用前景。在此,本文就唑来膦酸治疗恶性肿瘤骨转移的临床研究进展作一综述。Bone metastasis is the common complication of malignant tumor, especially of breast cancer, lung cancer and prostate cancer etc with the incidence rate above 30%-85%. Cancer patients often suffer from cancer-induced bone pain and hypercalcemia, which significantly lower quality of life. Zoledronic acid, as a third-generation bispbosphonate, can inhibit bone absorption through in- hibiting the activity of osteoclast and inducing the apoptosis of osteoclast. Zoledronic acid used in the treatment of bone metastasis of malignant tumor is paid more and more attention, and shows good application prospect. In this review, the progress in clinical studies on zoledronic acid in the treatment of bone metastasis of malignant tumor was reviewed.

关 键 词：唑来膦酸 恶性肿瘤 骨转移 临床应用 

分 类 号：R979.1[医药卫生—药品]